| CTRI Number |
CTRI/2025/01/079750 [Registered on: 29/01/2025] Trial Registered Prospectively |
| Last Modified On: |
19/12/2024 |
| Post Graduate Thesis |
Yes |
| Type of Trial |
Interventional |
|
Type of Study
|
Preventive Process of Care Changes |
| Study Design |
Randomized, Parallel Group, Placebo Controlled Trial |
|
Public Title of Study
|
Does periprocedural antibiotic prevent micturating cystourethrography (MCU) associated urinary tract infection in children? |
|
Scientific Title of Study
|
Periprocedural antibiotic prophylaxis compared to placebo in preventing voiding cystourethrography-associated urinary tract infection in children- A randomized controlled trial |
| Trial Acronym |
NIL |
|
Secondary IDs if Any
|
| Secondary ID |
Identifier |
| NIL |
NIL |
|
|
Details of Principal Investigator or overall Trial Coordinator (multi-center study)
|
| Name |
Dr Preeti Talli |
| Designation |
Junior resident |
| Affiliation |
Jawaharlal Institute of Post graduate Medical Education and Research (JIPMER) |
| Address |
Department of Paediatrics, 2nd floor, Women and Child block, JIPMER, Dhanvantari nagar, Puducherry- 605006
India
Pondicherry PONDICHERRY 605006 India |
| Phone |
9901136238 |
| Fax |
|
| Email |
pretally2@gmail.com |
|
Details of Contact Person Scientific Query
|
| Name |
Dr Sudarsan K |
| Designation |
Assistant Professor |
| Affiliation |
Jawaharlal Institute of Post graduate Medical Education and Research (JIPMER) |
| Address |
Department of Paediatrics, 2nd floor, Women and Child block, JIPMER, Dhanvantari nagar, Puducherry- 605006
India
Pondicherry PONDICHERRY 605006 India |
| Phone |
9855071507 |
| Fax |
|
| Email |
sudarsanjipmer@gmail.com |
|
Details of Contact Person Public Query
|
| Name |
Dr Sudarsan K |
| Designation |
Assistant Professor |
| Affiliation |
Jawaharlal Institute of Post graduate Medical Education and Research (JIPMER) |
| Address |
Department of Paediatrics, 2nd floor, Women and Child block, JIPMER, Dhanvantari nagar, Puducherry- 605006
India
Pondicherry PONDICHERRY 605006 India |
| Phone |
9855071507 |
| Fax |
|
| Email |
sudarsanjipmer@gmail.com |
|
|
Source of Monetary or Material Support
|
| JIPMER Intramural Research Fund (IMRF), JIPMER, Puducherry- 605006 |
|
|
Primary Sponsor
|
| Name |
Jawaharlal Institute of Post graduate Medical Education and Research, JIPMER |
| Address |
Dhanavantri nagar,
Pondicherry- 605006
India
|
| Type of Sponsor |
Government medical college |
|
|
Details of Secondary Sponsor
|
|
|
Countries of Recruitment
|
India |
|
Sites of Study
|
| No of Sites = 1 |
| Name of Principal
Investigator |
Name of Site |
Site Address |
Phone/Fax/Email |
| Dr Preeti Talli |
Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER) |
Pediatric Nephrology services, Department of Pediatrics, Women and Child Health block, JIPMER,
Dhanavantri nagar, Pondicherry - 605006 Pondicherry PONDICHERRY |
9901136238
pretally2@gmail.com |
|
|
Details of Ethics Committee
|
| No of Ethics Committees= 1 |
| Name of Committee |
Approval Status |
| JIPMER Institutional Ethics Committee- Interventional Studies |
Approved |
|
|
Regulatory Clearance Status from DCGI
|
|
|
Health Condition / Problems Studied
|
| Health Type |
Condition |
| Patients |
(1) ICD-10 Condition: N390||Urinary tract infection, site notspecified, |
|
|
Intervention / Comparator Agent
|
| Type |
Name |
Details |
| Intervention |
Peri-procedural Antibiotics (Co- trimoxazole) |
one randomized group of patients undergoing voiding cystourethrography receiving antibiotic Co-trimoxazole at 2 mg/Kg (Syrup Bactrim (40 mg/5 ml) at 0.25 ml/kg) in 2 divided doses- first dose 30-60 minutes prior to the procedure and the second dose 4-8 hours post-procedure |
| Comparator Agent |
Placebo group |
The other randomized group of patients undergoing Voiding cystourethrography receiving placebo at 0.25 ml/kg in 2 divided doses- first dose 30-60 minutes prior to the procedure and the second dose 4-8 hours post procedure |
|
|
Inclusion Criteria
|
| Age From |
3.00 Month(s) |
| Age To |
18.00 Year(s) |
| Gender |
Both |
| Details |
Children aged 3 months to 18 years undergoing voiding cystourethrography |
|
| ExclusionCriteria |
| Details |
1) Children on immunosuppressive medications like nephrotic syndrome or post kidney transplant recipients
2) Children with known allergy to cotrimoxazole/ radiocontrast agent or sulpha allergy
3) Patient who already has an indwelling urinary catheter on the day of voiding cystourethrography
4) Child having fever and/or signs and symptoms of urinary tract infection on the scheduled day of voiding cystourethrography |
|
|
Method of Generating Random Sequence
|
Stratified block randomization |
|
Method of Concealment
|
Sequentially numbered, sealed, opaque envelopes |
|
Blinding/Masking
|
Participant, Investigator, Outcome Assessor and Date-entry Operator Blinded |
|
Primary Outcome
|
| Outcome |
TimePoints |
| To compare the proportion of patients who develop symptomatic voiding cystourethrography-associated urinary tract infection within 7 days post procedure between the antibiotic prophylaxis group and placebo group in children aged 3 months to 18 years undergoing voiding cystourethrography |
Within 7 days post voiding cystourethrography |
|
|
Secondary Outcome
|
| Outcome |
TimePoints |
To compare the proportion of patients who have asymptomatic bacteriuria between days 2-7 post voiding cystourethrography in the antibiotic prophylaxis and placebo groups.
To compare the proportion of patients who develop symptomatic voiding cystourethrography-associated urinary tract infection between 7-14 days post procedure between the antibiotic prophylaxis group and placebo group
To determine the antibiotic sensitivity pattern in these children.
To identify the risk factors for developing post-voiding cystourethrography-associated urinary tract infection. |
2-14 days post voiding cystourethrography |
|
|
Target Sample Size
|
Total Sample Size="208" Sample Size from India="208"
Final Enrollment numbers achieved (Total)= "Applicable only for Completed/Terminated trials"
Final Enrollment numbers achieved (India)="Applicable only for Completed/Terminated trials" |
|
Phase of Trial
|
Phase 3/ Phase 4 |
|
Date of First Enrollment (India)
|
10/02/2025 |
| Date of Study Completion (India) |
Applicable only for Completed/Terminated trials |
| Date of First Enrollment (Global) |
Date Missing |
| Date of Study Completion (Global) |
Applicable only for Completed/Terminated trials |
|
Estimated Duration of Trial
|
Years="2" Months="0" Days="0" |
|
Recruitment Status of Trial (Global)
|
Not Applicable |
| Recruitment Status of Trial (India) |
Not Yet Recruiting |
|
Publication Details
|
N/A |
|
Individual Participant Data (IPD) Sharing Statement
|
Will individual participant data (IPD) be shared publicly (including data dictionaries)?
Response - NO
|
|
Brief Summary
|
The study shall be undertaken at the Department of Pediatrics, JIPMER from Jan 2025 for a period of 2 years after acquiring the Institutional Ethics Committee (IEC) clearance and CTRI registration prior to enrolment of the first patient. This study shall include patients aged 3 months to 18 years undergoing VCUG. When these patients come to the hospital for VCUG (absence of signs/symptoms of UTI at the time of presentation and a negative urine culture within the preceding 2 weeks are mandatory to undertake the test), they will be approached for possible enrollment into the trial. Written informed consent will be taken from the parents of the study participants (and assent from children 8 years or older) and the study will be conducted in accordance with the Declaration of Helsinki. Once the patients are enrolled, they will be randomly allocated to group A or group B based on which they will either receive antibiotic or placebo. The children already on antibiotic prophylaxis will be stratified and then allocated to group A or group B. The subjects will receive one dose of the drug (antibiotic/placebo) 30-60 minutes prior to the procedure and the second dose 4-8 hours after the procedure. VCUG will be performed under strict aseptic precautions as per standard protocols being followed in the radiology department of the institute. On the evening of the procedure, a telephonic call will be made to all the enrolled participants to enquire about development of any signs/ symptoms of UTI and if the child has taken the evening dose of the medicine (antibiotic/ placebo). Subsequently, all enrolled patients will be followed up for development of UTI over the next 7 days (considering the day of VCUG as day 1). Urine sample of those patients who present with signs and symptoms of urinary tract infection within 7 days post-VCUG will be collected and sent for urine routine and culture. They will be admitted in the Pediatrics ward and administered parenteral antibiotics as per ISPN 2023 guidelines. If patients do not develop signs/symptoms of UTI, they will undergo urine routine and culture testing to look for prevalence of asymptomatic bacteriuria and identify antibiotic sensitivity pattern. Ad per current practice, patients report to the pediatric nephrology clinic 2-7 days after VCUG to interpret the findings of VCUG and make further management decisions. If patients do not report to the pediatric nephrology clinic by day 5 post VCUG, a telephonic reminder will be sent to them apart from enquiring about the signs and symptoms of UTI that might have developed post VCUG.
|